Skip to content
Peptigraph home
Shop Peptides50% off*

Mazdutide for Diabetes: What the Evidence Shows

What human and animal studies show about Mazdutide for diabetes, how strong that evidence is, and what is still unproven.

Medical review pendingGLP-1 / glucagon dual agonistUpdated
Strongest evidence
Human RCT
Human studies
3
with an outcome for diabetes, in our evidence file (PubMed search, 2 Oct 2026)
Animal studies
None found
with an outcome for diabetes, in our evidence file (PubMed search, 2 Oct 2026)
Studies we summarised
3
with an outcome for diabetes

Evidence for diabetes

Each row is an outcome related to diabetes from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Mazdutide for diabetes: outcomes in published studies
OutcomeResultStudy typeSource
HbA1c at week 24 (primary)HbA1c changed by -2.15% with 6 mg and -1.57% with 4 mg versus -0.14% with placebo at week 24.Human RCTn = 320Nature 2026, PMID 41407859
Body weight at week 24Body weight changed by -7.81% with 6 mg and -5.61% with 4 mg versus -1.26% with placebo.Human RCTn = 320Nature 2026, PMID 41407859
HbA1c vs dulaglutideVersus dulaglutide 1.5 mg, HbA1c differed by -0.24% (4 mg) and -0.30% (6 mg) at week 28.Human RCTn = 731Nature 2026, PMID 41407860
Body weight vs dulaglutideBody weight differed by -3.78% (4 mg) and -5.76% (6 mg) versus dulaglutide.Human RCTn = 731Nature 2026, PMID 41407860
HbA1c at week 20 (primary)HbA1c changed by -1.41% to -1.67% with mazdutide versus -1.35% with dulaglutide and 0.03% with placebo at week 20.Human RCTDiabetes care 2024, PMID 37943529
Body weight at week 20Body weight changed by up to -7.1% with mazdutide versus -2.7% with dulaglutide and -1.4% with placebo at week 20.Human RCTDiabetes care 2024, PMID 37943529

Mazdutide and diabetes are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 2 Oct 2026). Grades follow our .

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4Nature 2026, PMID 41407859

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

Diabetes in plain terms

MedlinePlus defines diabetes as a disease in which blood glucose levels are too high.[4]

Glycaemic results

In a 20-week trial in Chinese adults with type 2 diabetes, HbA1c changed by -1.41% to -1.67% with mazdutide, -1.35% with dulaglutide and 0.03% with placebo.[3]

A phase 3 monotherapy trial randomized 320 participants to 4 mg or 6 mg of mazdutide or placebo for 24 weeks, followed by 24 weeks of extended treatment.[1]

A 731-participant trial compared 4 mg and 6 mg of mazdutide with 1.5 mg dulaglutide for 28 weeks.[2]

Registered HbA1c measures

The phase 2 record NCT04904913 registered change from baseline in HbA1c.[5]

The record NCT05606913 registered HbA1c change from baseline at week 28.[6]

The record NCT05607680 registered change from baseline in glycated hemoglobin A1c (HbA1c).[7]

Other peptides people research for diabetes

SemaglutideTirzepatideRetatrutideOrforglipronTesamorelinMOTS-cSurvodutideCagriSema
All peptides for diabetes, compared

Common questions

Does Mazdutide help with diabetes?

The strongest study we summarise for diabetes is human rct evidence, across 3 studies with an outcome for diabetes. A trial result is not an approval; see the legal status.

Is Mazdutide approved for diabetes?

No. Mazdutide is not FDA approved for any use, including diabetes.

What is the best peptide for diabetes?

There is no single answer. Our diabetes overview compares each candidate by evidence grade and legal status rather than by popularity.

Is mazdutide approved for type 2 diabetes?

No regulator in the cached lookups lists a mazdutide product; the diabetes data come from trials.

Calculated from drugs fda matches 0; emc results 0; health canada records 0; artg results 0. Formula: products found across the four lookups = 0

More on Mazdutide

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.Legal statusFDA, compounding and WADA status with dates.How to injectSites, syringe types and hygiene, step by step.BenefitsClaimed benefits next to what published studies measured.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1Mazdutide versus placebo in Chinese adults with type 2 diabetes.Nature · 2026PMID 41407859Accessed 2 Oct 2026
  2. 2Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.Nature · 2026PMID 41407860Accessed 2 Oct 2026
  3. 3Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.Diabetes care · 2024PMID 37943529Accessed 2 Oct 2026
  4. 4Official web pageOfficial web page · web page
  5. 5A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Chinese Overweight and Obese SubjectsClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
  6. 6Efficacy and Safety of IBI362 Versus Dulaglutide as add-on to Metformin and/or SGLT2 Inhibitor or TZD in Subjects With Type 2 Diabetes (DREAMS-2)ClinicalTrials.gov (U.S. National Library of Medicine) · 2022clinicaltrials.govAccessed 2 Oct 2026
  7. 7A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of IBI362 in Chinese Participants With Obesity or Overweight (GLORY-1)ClinicalTrials.gov (U.S. National Library of Medicine) · 2022clinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.